Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
Vir Biotechnology, Inc. (VIR) disclosed that major shareholder and director-affiliated entity SVF Endurance (Cayman) Limited reported two open-market sales of Vir common stock. On 11/24/2025, it sold 227,803 shares at a weighted average price of $6.1491, and on 11/25/2025 it sold 235,971 shares at a weighted average price of $6.38. The sales were made under a Rule 10b5-1 trading plan entered into on September 3, 2025. After these transactions, the reporting person indirectly beneficially owned 14,110,209 Vir common shares, held of record by SVF Endurance (Cayman) Limited.
Vir Biotechnology, Inc. reported an insider stock transaction by its EVP & Chief Financial Officer. On 11/17/2025, the officer sold 6,799 shares of Vir common stock at a price of $5.557 per share. The company states this was an automatic sale to cover tax withholding and remittance obligations tied to the vesting of restricted stock units, meaning it was done for tax purposes rather than discretionary selling. After this transaction, the officer beneficially owns 110,701 shares of Vir common stock, which includes 2,500 shares acquired on May 30, 2025 through an employee stock purchase program.
Vir Biotechnology (VIR) reported an insider transaction by its EVP, General Counsel and Corporate Secretary. On 11/05/2025, the officer sold 2,385 shares of common stock at $5.16 per share, as indicated by transaction code S. Following the sale, the officer beneficially owns 78,210 shares, held directly.
The filing notes the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 5, 2024.
Vir Biotechnology (VIR) reported Q3 2025 results with total revenue of $0.24 million and a net loss of $163.1 million (loss per share $1.17). Year-to-date, the company recorded a net loss of $395.1 million and used $365.9 million in operating cash.
Liquidity remained strong with $810.7 million in cash, cash equivalents and investments as of September 30, 2025, which management states is sufficient for at least twelve months. Q3 operating expenses totaled $173.7 million, driven by R&D of $151.5 million and SG&A of $22.2 million. The quarter included a $75.0 million milestone payment related to the Sanofi PRO-XTEN license; earlier in 2025, Vir paid $30.0 million under the restated Alnylam agreement and achieved a $17.5 million clinical milestone tied to tobevibart.
Clinical programs advanced: the ECLIPSE registrational program for chronic hepatitis delta has all trials underway, with ECLIPSE 1 enrollment completed ahead of plan and topline readouts for ECLIPSE 1–3 expected in Q1 2027. Oncology TCEs (VIR-5500, VIR-5818, VIR-5525) are in phase 1, with the first patient for VIR-5525 dosed in July 2025. Shares outstanding were 139,125,032 as of October 29, 2025.
Vir Biotechnology, Inc. furnished its quarterly results via an 8-K on November 5, 2025. The filing states that a press release announcing financial results for the quarter ended September 30, 2025 is attached as Exhibit 99.1 and incorporated by reference.
The company notes the information under Item 2.02 is being furnished and not deemed filed under the Exchange Act, limiting associated Section 18 liabilities. The common stock trades on the Nasdaq Global Select Market under the symbol VIR.
Vir Biotechnology (VIR) reported a Form 4 for insider activity. Vanina de Verneuil, EVP and General Counsel, executed an automatic sale of 1,365 shares of common stock at $5.863 on 11/03/2025 to satisfy tax withholding obligations upon RSU vesting.
After the transaction, she directly beneficially owns 80,595 shares. This total includes 2,500 shares acquired on May 30, 2025 through the employee stock purchase program.
Vir Biotechnology (VIR) director reported an open‑market sale of company stock. On 11/03/2025, the reporting person sold 22,000 shares of common stock at a weighted average price of $5.6385, coded “S”. The sale was made pursuant to a Rule 10b5‑1 trading plan adopted on 03/27/2025.
Following the transactions, the reporting person beneficially owned 1,210,391 shares, held directly. The shares were sold in multiple trades with prices ranging from $5.51 to $5.90.
Vir Biotechnology (VIR): Form 4 insider transactions disclosed. SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund (AIV M1) L.P. and managed by SB Investment Advisers (UK) Limited, reported open-market sales executed under a Rule 10b5-1 plan entered on September 3, 2025. On October 28, 2025, it sold 24,453 shares at a weighted average price of $6.5025, and on October 29, 2025, it sold 100 shares at $6.49. Following these trades, indirect beneficial ownership stood at 14,573,983 shares. The reporting relationship indicates Director status, and the filing is made by more than one reporting person.
Vir Biotechnology (VIR): insider share sales disclosed. SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund, reported open‑market sales of VIR common stock pursuant to a Rule 10b5‑1 plan entered on September 3, 2025.
On October 24, 2025, 46,696 shares were sold at a weighted average price of $5.9595, with trades ranging from $5.92 to $6.0212. On October 27, 2025, 66,403 shares were sold at a weighted average price of $6.0477, with trades ranging from $5.93 to $6.18. Following these transactions, 14,598,536 shares were beneficially owned on an indirect basis through SVF Endurance, as noted in the filing’s footnotes regarding SoftBank Vision Fund’s management structure.
Vir Biotechnology (VIR): insider transaction SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund, reported open‑market sales made pursuant to a Rule 10b5‑1 trading plan entered into on September 3, 2025.
It sold 144,266 shares on October 22, 2025 at a weighted average price of $6.1529, and 154,383 shares on October 23, 2025 at a weighted average price of $5.9898. After these transactions, the reporting person disclosed beneficial ownership of 14,711,635 shares, held indirectly.